Antoinette Hollestelle

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus, The Netherlands
    Breast Cancer Res Treat 121:53-64. 2010
  2. ncbi A genome-wide association scan on estrogen receptor-negative breast cancer
    Jingmei Li
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden
    Breast Cancer Res 12:R93. 2010
  3. ncbi Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Breast Cancer Res Treat 128:79-84. 2011
  4. ncbi Discovering moderate-risk breast cancer susceptibility genes
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    Curr Opin Genet Dev 20:268-76. 2010
  5. ncbi Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 122:125-33. 2010
  6. ncbi Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines
    Marijke Wasielewski
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 113:285-91. 2009
  7. ncbi Exon expression arrays as a tool to identify new cancer genes
    Mieke Schutte
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    PLoS ONE 3:e3007. 2008
  8. ncbi The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype
    Hanne Meijers-Heijboer
    Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
    Am J Hum Genet 72:1308-14. 2003
  9. ncbi Low-risk susceptibility alleles in 40 human breast cancer cell lines
    Muhammad Riaz
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Cancer 9:236. 2009
  10. ncbi Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute Be414, Erasmus MC, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Mol Cancer Res 5:195-201. 2007

Collaborators

Detail Information

Publications13

  1. ncbi Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus, The Netherlands
    Breast Cancer Res Treat 121:53-64. 2010
    ....
  2. ncbi A genome-wide association scan on estrogen receptor-negative breast cancer
    Jingmei Li
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden
    Breast Cancer Res 12:R93. 2010
    ..ER status of breast cancer is important clinically, and is used both as a prognostic indicator and treatment predictor. In this study, we focused on identifying genetic markers associated with ER-negative breast cancer risk...
  3. ncbi Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Breast Cancer Res Treat 128:79-84. 2011
    ..Importantly, results from the current study suggest that KRAS-variant frequencies might be increased among BRCA1 carriers, but solid proof requires confirmation in a larger cohort of BRCA1 carriers...
  4. ncbi Discovering moderate-risk breast cancer susceptibility genes
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    Curr Opin Genet Dev 20:268-76. 2010
    ..As a result, discovery of moderate-risk breast cancer genes requires conclusive statistical evidence from association studies of hundreds of breast cancer cases and population-matched controls...
  5. ncbi Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 122:125-33. 2010
    ..Together, our observations suggest that alpha-catenin may be a new tumor suppressor gene that operates in the E-cadherin tumor suppressor pathway...
  6. ncbi Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines
    Marijke Wasielewski
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 113:285-91. 2009
    ..Cell lines UACC812 and SUM102PT thus are the first human CHEK2 null cell lines reported and should therefore be a major help in further unraveling the function of CHEK2 mutations in carcinogenesis...
  7. ncbi Exon expression arrays as a tool to identify new cancer genes
    Mieke Schutte
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    PLoS ONE 3:e3007. 2008
    ..As genetic changes in cancer are sample specific, we tested the ability of PAC to identify aberrantly expressed exons in single samples...
  8. ncbi The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype
    Hanne Meijers-Heijboer
    Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
    Am J Hum Genet 72:1308-14. 2003
    ..The unequivocal definition of the HBCC phenotype opens new avenues to search for this putative HBCC-susceptibility gene...
  9. ncbi Low-risk susceptibility alleles in 40 human breast cancer cell lines
    Muhammad Riaz
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Cancer 9:236. 2009
    ..The mechanism by which the low-risk SNPs confer breast cancer risks is currently unclear. The breast cancer association consortium BCAC has hypothesized that the low-risk SNPs modulate expression levels of nearby located genes...
  10. ncbi Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute Be414, Erasmus MC, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Mol Cancer Res 5:195-201. 2007
    ..001). These results suggest that there is a fine distinction between the signaling activators and downstream effectors of the oncogenic PI3K and RAS pathways in breast epithelium and those in other tissues...
  11. ncbi BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants
    Fons Elstrodt
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer Res 66:41-5. 2006
    ..These three new human BRCA1 mutant cell lines thus seem to be representative breast cancer models that could aid in further unraveling of the function of BRCA1...
  12. ncbi Representational difference analysis as a tool in the search for new tumor suppressor genes
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    Methods Mol Med 103:143-59. 2005
    ..Here, we provide a detailed protocol of the RDA procedure, including reflections on frequently encountered technical problems and on the particulars of its application in cancer...
  13. ncbi Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
    Hanne Meijers-Heijboer
    Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
    Nat Genet 31:55-9. 2002
    ....